Pembrolizumab Plus Autologous Dendritic Cell Vaccine in Patients with PD-L1 Negative Advanced Mesothelioma Who Have Failed Prior Therapies

NCT03546426 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

18

Enrollment

OTHER

Sponsor class

Conditions

Mesothelioma, Malignant
PD-L1 Negative
Advanced Cancer
Progressive Disease

Interventions

DRUG: Pembrolizumab
BIOLOGICAL: Autologous dendritic cells
DRUG: Interleukin-2

Sponsor

Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS